Alimentary TractGenetic factors determine extent of bone loss in inflammatory bowel disease☆
Section snippets
Subjects
The study group consisted of 83 patients with IBD. Sixty (72%) patients had Crohn's disease, and 23 (28%) patients had ulcerative colitis. The diagnosis of IBD was established on the basis of standard clinical, radiologic, endoscopic, and pathologic criteria. Exclusion criteria included borderline manifestations; unclear subtype or uncertain diagnosis; former organ transplantation; other systemic inflammatory disease; medication with bone-toxic agents (exept steroids) such as heparin,
Study population
The characteristics of the study population at baseline are summarized in Table 1.Empty Cell n % Type of IBD Crohn's disease 60 Involvement of Colon 50 83 Distal small bowel 45 75 Upper GI tract 10 17 Resection of Ileocecal valve 29 48 Colon (subtotal or total) 11 19 Upper GI tract 4 7 Ulcerative colitis 23 Pancolitis 10 43.5 Left-sided colitis 6 26 Proctosigmoiditis 7 30.5 Sex Male 45 54 Female 38 46 Pre/postmenopausal 29/9 Empty Cell Mean SD Median Range Age (yr) 37 14 33 17–75 Duration of
Discussion
Our study shows that variations of the IL-6 and IL1-ra genes, but not the hsp 70 gene, are independent determinants of bone loss in the setting of IBD. The IL-6 and IL1-ra genes have been identified as independent predictors of bone loss in the setting of postmenopausal osteoporosis. That they function in a similar way in our study group of IBD patients may signify that they specifically determine the response of bone to different stressors such as the postmenopausal status or systemic
References (51)
- et al.
Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
Am J Gastroenterol
(1999) Inflammatory bowel disease: etiology and pathogenesis
Gastroenterology
(1998)- et al.
IBD-associated bone loss: is inflammation the explanation? (letter)
Gastroenterology
(1997) - et al.
A four-year longitudinal study of bone loss in patients with inflammatory bowel disease
Bone Miner
(1993) - et al.
Colitis causes bone loss in rats through suppression of bone formation
Gastroenterology
(1996) - et al.
Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis
Gastroenterology
(1994) - et al.
Gender, age and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients
Am J Gastroenterol
(1999) - et al.
Allelic variation at the Interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine
Bone
(1998) - et al.
Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study
Scand J Gastroenterol
(1999) Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
Am J Gastroenterol
(1997)
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
Aliment Pharmacol Ther
The pathophysiologic roles of interleukin-6 in human disease
Ann Intern Med
Bone marrow, cytokines and bone remodeling
N Engl J Med
Role of cytokines in bone resorption
Bone
Molecular chaperones and disease
Inflamm Res
The different expression of proteins recognized by monoclonal anti-heat shock protein 70 (hsp 70) antibody inhuman colonic diseases
Electrophoresis
Polymorphism of heat-shock protein gene HSP 70-2 in Crohn disease: possible genetic markers for two forms of Crohn disease
Scand J Gastroenterol
Molecular chaperones stimulate bone resorption
Calcif Tissue Int
The Escherischia coli chaperonin 60 (gro EL) is a potent stimulator of osteoclast formation
J Bone Miner Res
Effect of experimental colitis on bone metabolism in the rat
Digestion
A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine
J Bone Miner Res
The 1993–94 Genethom human genetic linkage map
Nat Genet
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report
Osteoporos Int
Inflammation mediated osteopenia in the rat: a new animal model for pathological loss of bone mass
Endocrinology
Review article: osteoporosis, corticosteroids and inflammatory bowel disease
Aliment Pharmacol Ther
Cited by (108)
Effects of Digestive Diseases on Bone Metabolism
2011, Pediatric Gastrointestinal and Liver DiseaseEffects of Digestive Diseases on Bone Metabolism
2010, Pediatric Gastrointestinal and Liver DiseaseGenomic Assessment of Inflammatory Bowel Disease
2010, Essentials of Genomic and Personalized MedicineBone Health in Patients With Inflammatory Bowel Diseases
2020, Journal of Clinical DensitometryCitation Excerpt :One study from the Netherlands showed that individuals with polymorphism of the IL-1beta and IL-1 receptor (IL-1ra) (particularly carriers of IL1B-511*2, which leads to hypersecretion of IL-1) had a higher risk of presenting with low bone mass in IBD (26). Another study from Germany showed that noncarriage of the 240-base pair allele of the IL-1ra gene and carriage of the 130-base pair allele of IL-6 were independently associated with increased bone loss (27). This suggests a genetic predisposition to increased bone loss in some patients with IBD.
Signaling pathways associated with bone loss in inflammatory bowel disease
2023, Annals of GastroenterologyAdvances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases
2023, Frontiers in Pharmacology
- ☆
Address requests for reprints to: Claudia M. S. Schulte, M.D., Division of Endocrinology, Department of Internal Medicine, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany. e-mail: [email protected]; fax: (49) 201-268988.